Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 229

1.

Analysis of gene expression in rheumatoid arthritis and related conditions offers insights into sex-bias, gene biotypes and co-expression patterns.

Platzer A, Nussbaumer T, Karonitsch T, Smolen JS, Aletaha D.

PLoS One. 2019 Jul 25;14(7):e0219698. doi: 10.1371/journal.pone.0219698. eCollection 2019.

2.

Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review.

Schlager L, Loiskandl M, Aletaha D, Radner H.

Rheumatology (Oxford). 2019 Jul 19. pii: kez278. doi: 10.1093/rheumatology/kez278. [Epub ahead of print]

PMID:
31325305
3.

Does Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug Therapy Improve upon Methotrexate as the Initial Treatment of Choice for a Rheumatoid Arthritis Patient?

Aletaha D, Smolen JS.

Rheum Dis Clin North Am. 2019 Aug;45(3):315-324. doi: 10.1016/j.rdc.2019.04.002. Epub 2019 Jun 5. Review.

PMID:
31277746
4.

Disease activity assessment in patients with psoriatic arthritis.

Kerschbaumer A, Smolen JS, Aletaha D.

Best Pract Res Clin Rheumatol. 2018 Jun;32(3):401-414. doi: 10.1016/j.berh.2018.08.004. Epub 2018 Oct 11. Review.

PMID:
31171311
5.

Risk of Developing Additional Immune-Mediated Manifestations: A Retrospective Matched Cohort Study.

Aletaha D, Epstein AJ, Skup M, Zueger P, Garg V, Panaccione R.

Adv Ther. 2019 Jul;36(7):1672-1683. doi: 10.1007/s12325-019-00964-z. Epub 2019 May 17.

PMID:
31102202
6.

Risk profiling for a refractory course of rheumatoid arthritis.

Bécède M, Alasti F, Gessl I, Haupt L, Kerschbaumer A, Landesmann U, Loiskandl M, Supp GM, Smolen JS, Aletaha D.

Semin Arthritis Rheum. 2019 Feb 8. pii: S0049-0172(18)30553-5. doi: 10.1016/j.semarthrit.2019.02.004. [Epub ahead of print]

7.

Achieving Clinical Remission for Patients With Rheumatoid Arthritis.

Aletaha D, Smolen JS.

JAMA. 2019 Feb 5;321(5):457-458. doi: 10.1001/jama.2018.21249. No abstract available.

PMID:
30721278
8.

Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider.

Unger J, Putrik P, Buttgereit F, Aletaha D, Bianchi G, Bijlsma JWJ, Boonen A, Cikes N, Dias JM, Falzon L, Finckh A, Gossec L, Kvien TK, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Dejaco C, Ramiro S.

RMD Open. 2018 Dec 5;4(2):e000756. doi: 10.1136/rmdopen-2018-000756. eCollection 2018.

9.

EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology.

Dejaco C, Putrik P, Unger J, Aletaha D, Bianchi G, Bijlsma JW, Boonen A, Cikes N, Finckh A, Gossec L, Kvien TK, Madruga Dias J, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Ramiro S, Buttgereit F.

RMD Open. 2018 Dec 5;4(2):e000780. doi: 10.1136/rmdopen-2018-000780. eCollection 2018.

10.

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity.

Landewé R, Ritchlin CT, Aletaha D, Zhang Y, Ganz F, Hojnik M, Coates LC.

Rheumatology (Oxford). 2019 Jun 1;58(6):1025-1033. doi: 10.1093/rheumatology/key417.

11.

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study.

Norvang V, Sexton J, Kristianslund EK, Olsen IC, Uhlig T, Bakland G, Krøll F, Rødevand E, Wierød A, Kvien TK, Smolen JS, Aletaha D, Haavardsholm EA.

RMD Open. 2018 Oct 26;4(2):e000773. doi: 10.1136/rmdopen-2018-000773. eCollection 2018.

12.

Diagnosis and Management of Rheumatoid Arthritis: A Review.

Aletaha D, Smolen JS.

JAMA. 2018 Oct 2;320(13):1360-1372. doi: 10.1001/jama.2018.13103. Review.

PMID:
30285183
13.

Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?

Michelsen B, Sexton J, Smolen JS, Aletaha D, Krogh NS, van der Heijde D, Kvien TK, Hetland ML.

Ann Rheum Dis. 2018 Dec;77(12):1736-1741. doi: 10.1136/annrheumdis-2018-213463. Epub 2018 Sep 20.

PMID:
30237203
14.

Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey.

Roodenrijs NMT, de Hair MJH, van der Goes MC, Jacobs JWG, Welsing PMJ, van der Heijde D, Aletaha D, Dougados M, Hyrich KL, McInnes IB, Mueller-Ladner U, Senolt L, Szekanecz Z, van Laar JM, Nagy G; whole EULAR Task Force on development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis.

Ann Rheum Dis. 2018 Dec;77(12):1705-1709. doi: 10.1136/annrheumdis-2018-213687. Epub 2018 Sep 7.

PMID:
30194273
15.

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.

Stamm TA, Machold KP, Aletaha D, Alasti F, Lipsky P, Pisetsky D, Landewe R, van der Heijde D, Sepriano A, Aringer M, Boumpas D, Burmester G, Cutolo M, Ebner W, Graninger W, Huizinga T, Schett G, Schulze-Koops H, Tak PP, Martin-Mola E, Breedveld F, Smolen J.

Arthritis Res Ther. 2018 Aug 9;20(1):174. doi: 10.1186/s13075-018-1667-z.

16.

Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases.

Harrison N, Poeppl W, Miksch M, Machold K, Kiener H, Aletaha D, Smolen JS, Forstner C, Burgmann H, Lagler H.

Vaccine. 2018 Aug 6;36(32 Pt B):4875-4879. doi: 10.1016/j.vaccine.2018.06.065. Epub 2018 Jul 3.

PMID:
29980390
17.

Are we failing patients in our assessment of treatment failure?

Nikiphorou E, Aletaha D, Bukhari M.

Rheumatology (Oxford). 2019 Apr 1;58(4):561-562. doi: 10.1093/rheumatology/key107. No abstract available.

PMID:
29897585
18.

To DAPSA or not to DAPSA? That is not the question.

Schoels MM, Smolen JS, Aletaha D.

Ann Rheum Dis. 2019 Jul;78(7):e61. doi: 10.1136/annrheumdis-2018-213548. Epub 2018 May 5. No abstract available.

PMID:
29730635
19.

Missing pebble in the mosaic of rheumatic diseases and mental health: younger does not always mean happier.

Alunno A, Studenic P, Wiek D, Balážová P, Aletaha D.

Ann Rheum Dis. 2019 Jun;78(6):e54. doi: 10.1136/annrheumdis-2018-213611. Epub 2018 Apr 28. No abstract available.

PMID:
29705744
20.

Early response to therapy predicts 6-month and 1-year disease activity outcomes in psoriatic arthritis patients.

Schoels MM, Landesmann U, Alasti F, Baker D, Smolen JS, Aletaha D.

Rheumatology (Oxford). 2018 Jun 1;57(6):969-976. doi: 10.1093/rheumatology/key004.

PMID:
29481661
21.

Tofacitinib for Psoriatic Arthritis.

Aletaha D, Kerschbaumer A, Smolen JS.

N Engl J Med. 2018 Feb 22;378(8):775. doi: 10.1056/NEJMc1715189. No abstract available.

PMID:
29469555
22.

Rheumatoid arthritis.

Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K.

Nat Rev Dis Primers. 2018 Feb 8;4:18001. doi: 10.1038/nrdp.2018.1. Review.

PMID:
29417936
23.

The effects of structural damage on functional disability in psoriatic arthritis.

Kerschbaumer A, Baker D, Smolen JS, Aletaha D.

Ann Rheum Dis. 2017 Dec;76(12):2038-2045. doi: 10.1136/annrheumdis-2017-211433. Epub 2017 Aug 23.

PMID:
28835465
24.

Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis patients.

Aletaha D, Snedecor SJ, Ektare V, Xue M, Bao Y, Garg V.

Clinicoecon Outcomes Res. 2017 Jul 28;9:451-458. doi: 10.2147/CEOR.S136327. eCollection 2017.

25.

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.

Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D.

Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6. Erratum in: Ann Rheum Dis. 2018 Mar;77(3):472.

26.

Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition.

Schoels M, Alasti F, Smolen JS, Aletaha D.

Arthritis Res Ther. 2017 Jul 4;19(1):155. doi: 10.1186/s13075-017-1346-5.

27.

Clinical meaning and implications of serum hemoglobin levels in patients with rheumatoid arthritis.

Padjen I, Öhler L, Studenic P, Woodworth T, Smolen J, Aletaha D.

Semin Arthritis Rheum. 2017 Oct;47(2):193-198. doi: 10.1016/j.semarthrit.2017.03.001. Epub 2017 Mar 8.

PMID:
28385457
28.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Review.

29.

Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.

Aletaha D, Bingham CO 3rd, Tanaka Y, Agarwal P, Kurrasch R, Tak PP, Popik S.

Lancet. 2017 Mar 25;389(10075):1206-1217. doi: 10.1016/S0140-6736(17)30401-4. Epub 2017 Feb 16. Erratum in: Lancet. 2017 May 20;389(10083):1980.

PMID:
28215362
30.

[Rheumatoid arthritis].

Aletaha D, Kerschbaumer A.

Z Rheumatol. 2017 Feb;76(1):8-14. doi: 10.1007/s00393-016-0251-7. Review. German.

PMID:
28058499
31.

EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis.

van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJ, Brouwer E, Codreanu C, Combe B, Fonseca JE, Hetland ML, Humby F, Kvien TK, Niedermann K, Nuño L, Oliver S, Rantapää-Dahlqvist S, Raza K, van Schaardenburg D, Schett G, De Smet L, Szücs G, Vencovský J, Wiland P, de Wit M, Landewé RL, van der Helm-van Mil AH.

Ann Rheum Dis. 2017 Mar;76(3):491-496. doi: 10.1136/annrheumdis-2016-209846. Epub 2016 Oct 6.

PMID:
27991858
32.

2016 update of the EULAR recommendations for the management of early arthritis.

Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM, Bakkers M, Brodin N, Burmester GR, Codreanu C, Conway R, Dougados M, Emery P, Ferraccioli G, Fonseca J, Raza K, Silva-Fernández L, Smolen JS, Skingle D, Szekanecz Z, Kvien TK, van der Helm-van Mil A, van Vollenhoven R.

Ann Rheum Dis. 2017 Jun;76(6):948-959. doi: 10.1136/annrheumdis-2016-210602. Epub 2016 Dec 15.

33.

The EULAR points to consider for health professionals undertaking musculoskeletal ultrasound for rheumatic and musculoskeletal diseases.

Siddle HJ, Mandl P, Aletaha D, Vliet Vlieland TP, Backhaus M, Cornell P, D'Agostino MA, Ellegaard K, Iagnocco A, Jakobsen B, Jasinski T, Kildal NH, Lehner M, Möller I, Supp GM, O'Connor P, Redmond AC, Naredo E, Wakefield RJ.

Ann Rheum Dis. 2018 Feb;77(2):311-313. doi: 10.1136/annrheumdis-2016-210741. Epub 2016 Dec 9. No abstract available.

34.

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria.

Smolen JS, Aletaha D, Gruben D, Zwillich SH, Krishnaswami S, Mebus C.

Arthritis Rheumatol. 2017 Apr;69(4):728-734. doi: 10.1002/art.39996. Epub 2017 Mar 8.

35.

Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities.

Radner H, Yoshida K, Tedeschi S, Studenic P, Frits M, Iannaccone C, Shadick NA, Weinblatt M, Aletaha D, Smolen JS, Solomon DH.

Arthritis Rheumatol. 2017 Apr;69(4):720-727. doi: 10.1002/art.39988.

36.

An overview of psoriatic arthritis - epidemiology, clinical features, pathophysiology and novel treatment targets.

Kerschbaumer A, Fenzl KH, Erlacher L, Aletaha D.

Wien Klin Wochenschr. 2016 Nov;128(21-22):791-795. Epub 2016 Nov 7. Review.

37.

Rheumatoid arthritis.

Smolen JS, Aletaha D, McInnes IB.

Lancet. 2016 Oct 22;388(10055):2023-2038. doi: 10.1016/S0140-6736(16)30173-8. Epub 2016 May 3. Review. Erratum in: Lancet. 2016 Oct 22;388(10055):1984.

PMID:
27156434
38.

Information technology concerning SDAI and CDAI.

Aletaha D, Bécède M, Smolen JS.

Clin Exp Rheumatol. 2016 Sep-Oct;34(5 Suppl 101):S45-S48. Epub 2016 Oct 18. Review.

40.

Fever of unknown origin (FUO) revised.

Unger M, Karanikas G, Kerschbaumer A, Winkler S, Aletaha D.

Wien Klin Wochenschr. 2016 Nov;128(21-22):796-801. Epub 2016 Sep 26. Review.

41.

Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis.

Choy E, Aletaha D, Behrens F, Finckh A, Gomez-Reino J, Gottenberg JE, Schuch F, Rubbert-Roth A.

Rheumatology (Oxford). 2017 May 1;56(5):689-697. doi: 10.1093/rheumatology/kew271. Review.

PMID:
27550301
42.

Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression.

Aletaha D, Alasti F, Smolen JS.

Ann Rheum Dis. 2017 Feb;76(2):418-421. doi: 10.1136/annrheumdis-2016-209511. Epub 2016 Jul 25.

PMID:
27457512
43.

The many faces of psoriatic arthritis - a challenge to treatment to target?

Aletaha D.

Reumatologia. 2016;54(1):1-2. doi: 10.5114/reum.2016.58753. Epub 2016 Mar 23. No abstract available.

44.

Therapeutic implications of autoantibodies in rheumatoid arthritis.

Aletaha D, Blüml S.

RMD Open. 2016 May 17;2(1):e000009. doi: 10.1136/rmdopen-2014-000009. eCollection 2016. Review.

45.

Clinical joint inactivity predicts structural stability in patients with established rheumatoid arthritis.

Gärtner M, Sigmund IK, Alasti F, Supp G, Radner H, Machold K, Smolen JS, Aletaha D.

RMD Open. 2016 Apr 7;2(1):e000241. doi: 10.1136/rmdopen-2016-000241. eCollection 2016.

46.

Glucocorticoid Effect on Radiographic Progression in Placebo Arms of Rheumatoid Arthritis Biologics Trials.

Boers M, Aletaha D, Mela CM, Baker DG, Smolen JS.

J Rheumatol. 2016 Jun;43(6):1024-6. doi: 10.3899/jrheum.150932. Epub 2016 Apr 1.

PMID:
27036379
47.

Management of rheumatoid arthritis: what happens and what does not happen in real life.

Aletaha D.

Rheumatol Int. 2016 Feb;36(2):167-8. doi: 10.1007/s00296-015-3402-2. Epub 2015 Dec 19. No abstract available.

PMID:
26687684
48.

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.

Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewé R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Cañete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D.

Ann Rheum Dis. 2016 Mar;75(3):499-510. doi: 10.1136/annrheumdis-2015-208337. Epub 2015 Dec 7.

PMID:
26644232
49.

Defining remission and treatment success using the DAPSA score: response to letter by Helliwell and Coates.

Schoels MM, Aletaha D, Smolen JS.

Ann Rheum Dis. 2015 Dec;74(12):e67. doi: 10.1136/annrheumdis-2015-208521. Epub 2015 Oct 22. No abstract available.

PMID:
26493815
50.

Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis (DAPSA). A brief review.

Smolen JS, Schoels M, Aletaha D.

Clin Exp Rheumatol. 2015 Sep-Oct;33(5 Suppl 93):S48-50. Epub 2015 Oct 15. Review.

PMID:
26471734

Supplemental Content

Loading ...
Support Center